
Tenax Therapeutics, Inc.
OrganizationHeard in 1 episode across 1 show since Aug 2026
Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing novel cardiopulmonary therapies. The company's primary development programs target pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 1 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
| Nov 2026 | 0 |
Email alert
Email me when Tenax Therapeutics, Inc. comes up on a podcast
One email a week at most, with the new episodes that mention Tenax Therapeutics, Inc.. Free, no account needed, unsubscribe in one click.
What experts have said about Tenax Therapeutics, Inc.
2 statements · 2 negative
Tenax Therapeutics shares fell more than 90% in one day.
“the shares plummeted over 90% today.”
Open the episode · Berkshire Jumps, Monday.com Falls, Tenax PlummetsListen at 3:39
Tenax Therapeutics has about $50 million market capitalization after erasing roughly $450 million.
“It's Only now about $50 million in market cap but of course it had erased about 450 million.”
Open the episode · Berkshire Jumps, Monday.com Falls, Tenax PlummetsListen at 4:18
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring Tenax Therapeutics, Inc., newest first